PRIMARY STUDY
Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials
Key Findings: Nabiximols showed a positive response in treating spasticity in patients with multiple sclerosis compared with placebo, with lower average daily Spasticity NRS scores, daily spasm counts, and MAS scores for combinations of muscle groups over 12 weeks.
Type of Study: Clinical Meta-analysis
Study Sample Size: 375
Study Result: Positive
Research Location(s): United Kingdom, United States
Year of Pub: 2023
Cannabinoids Studied: Pharma THC:CBD
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype II
Route of Administration: Sublingual/Oromucosal
Citation: Nicholas J, et al. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials. Mult Scler Relat Disord. 2023; 75:104745. doi: 10.1016/j.msard.2023.104745
Authors: Nicholas J, Lublin F, Klineova S, Berwaerts J, Chinnapongse R, Checketts D, Javaid S, Steinerman JR
